Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study.

Beatrice Nolan Johnny N MahlanguIngrid PabingerGuy Aaron Young Barbara A KonkleChris BarnesKeiji NogamiElena SantagostinoK John PasiLiane KhooBent WindingHuixing YuanJoachim FruebisDan RudinJohannes Oldenburg

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2020)

ASPIRE results, which include up to 5 years of follow-up data, confirm earlier reports on the consistent and well-characterized safety and efficacy of rFVIIIFc treatment for severe haemophilia A.

Keyphrases

early onset
emergency department
electronic health record
big data
drug induced
deep learning